Skip to Content Facebook Feature Image

High-Value Deals, Growing Global Reach: Chongqing Visit by Eurasian Enterprises Delivers in Both Scale and Substance

Business

High-Value Deals, Growing Global Reach: Chongqing Visit by Eurasian Enterprises Delivers in Both Scale and Substance
Business

Business

High-Value Deals, Growing Global Reach: Chongqing Visit by Eurasian Enterprises Delivers in Both Scale and Substance

2026-11-16 18:10 Last Updated At:18:20

CHONGQING, China--(BUSINESS WIRE)--Nov 16, 2026--

The Chongqing Visit by Eurasian Enterprises took place on November 12–13 under the theme “Chongqing: Forging New Connections Across Eurasia.” The event featured one industry matchmaking conference, 16 targeted matchmaking sessions, nine industrial site visits across Chongqing’s districts and counties, and four showcases of cooperation outcomes. Focusing on key sectors such as intelligent connected new energy vehicles, advanced materials, smart equipment, and biomedicine, the event facilitated business discussions and yielded a range of high-value cooperation outcomes with strong potential for implementation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116550238/en/

The event attracted 195 foreign-invested enterprises and institutions and more than 260 international delegates from 29 countries and regions. Nearly half of the participating companies were Fortune Global 500 companies, industry leaders, or hidden champions. Over 70% were represented by executives at vice president level or above, while nearly 80% operated in sectors aligned with Chongqing’s “3+3+6+18” System of Modern Manufacturing Clusters. More than 70% had yet to establish a presence in Chongqing, while foreign-invested companies already operating in the city also explored opportunities to increase investment and expand production. Together, these developments reflected Chongqing’s growing reach in attracting new investors worldwide.

A total of 28 cooperation projects were signed, with a combined contract value exceeding RMB20 billion. The projects covered both inbound foreign investment and the overseas expansion of local enterprises. The event also saw the launch of the CITIC Goldstone Chongqing Fund for Specialized and Innovative Enterprises and the European Market Expansion & Localization Shared Services Center, laying the groundwork for sustained industrial cooperation.

Chongqing also released a series of investment opportunity lists and business guides. The Opportunity List for High-Quality Industrial Development in Chongqing identified 180 investment opportunities in advanced manufacturing and modern services, representing a combined investment value of RMB480 billion. The Guide to Overseas Expansion Services for Chongqing Enterprises provided comprehensive guidance on logistics, cross-border industrial and financial services, intellectual property, and other aspects of international business operations. The Product Catalog of Selected Chongqing Enterprises featured approximately 500 products from 311 companies. Together, these resources formed an integrated package of investment opportunities, overseas expansion services, and product information, providing practical guidance for foreign investors seeking opportunities in Chongqing and local enterprises looking to expand into Eurasian markets.

Chongqing Visit by Eurasian Enterprises Delivers in Both Scale and Substance

Chongqing Visit by Eurasian Enterprises Delivers in Both Scale and Substance

SAN DIEGO--(BUSINESS WIRE)--Nov 16, 2026--

Seawolf Therapeutics (“Seawolf”) today announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116723769/en/

Founding investor Versant Ventures led the seed round, followed by the Series A financing with Versant, MPM BioImpact, and Novartis Venture Fund (NVF), and participation from Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, Pathway to Cures (the philanthropic venture arm of the National Bleeding Disorders Foundation), and others.

Seawolf also announced a multi-target research collaboration and exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications for up to $1.2 billion in research, development & commercial milestones, as well as tiered royalties on sales of any products resulting from the collaboration.

“Seawolf is charting a new course in patient care through LNP-based DNA medicines,” said Elizabeth Alcamo, Ph.D., president and CEO. “With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs.”

The funds will be used to advance Seawolf’s portfolio of therapeutics that leverage its redosable lipid nanoparticle (LNP)-based DNA delivery system, TRIDENT™ ( T argeted R NA- I nduced D NA E xpression via N uclear T ranslocation). TRIDENT matches the potency, redosability, safety and scalability of RNA-based LNP therapies but overcomes their short-lived expression by delivering DNA-based payloads. To do so, the TRIDENT system consists of a proprietary LNP carrying an immune quiet DNA that encodes a therapeutic transgene and an auxiliary factor that facilitates nuclear access. Therapies built with the TRIDENT technology are potent, durable, have a clean safety profile in primates and -- unlike virus-based DNA platforms -- are redosable, providing the ability to fine-tune or supplement dosing through repeat administration.

The TRIDENT system can be deployed across a broad range of therapeutic areas, including replacing mutant genes and expressing biologics systemically. The company has demonstrated proof-of-concept of the applicability of the technology in both primates and murine preclinical models of metabolic and rare diseases.

“Nucleic acid-based therapies have advanced dramatically over the past decade,” said Tom Woiwode, Ph.D., managing director at Versant and chair of Seawolf’s board. “The Seawolf team is now delivering on the promise of using DNA to drive robust and long-term expression of therapeutic proteins directly from the patient’s own cells. I look forward to seeing this groundbreaking technology transform treatment options for patients.”

About Seawolf Therapeutics

Seawolf Therapeutics is a privately held biotechnology company dedicated to transforming patient outcomes through the use of its proprietary LNP-based DNA delivery platform. The company’s TRIDENT™ technology achieves the elusive goal of delivering DNA into the nucleus of cells to enable the long-term, stable expression of therapeutic proteins, using a non-immunogenic and redosable format. Headquartered in San Diego, CA, the company is backed by top-tier investors including Versant Ventures, MPM BioImpact, and Novartis Venture Fund. For more information, visit www.seawolftx.com or follow us on LinkedIn.

Elizabeth Alcamo, PhD, president and CEO, Seawolf Therapeutics

Elizabeth Alcamo, PhD, president and CEO, Seawolf Therapeutics

Recommended Articles